Terms: = Brain cancer AND MYC, c-Myc, 4609, ENSG00000136997
1059 results:
1. PL-hMSC and CH-hMSC derived soluble factors inhibit proliferation but improve hGBM cell migration by activating TGF-β and inhibiting Wnt signaling.
Uthanaphun T; Manochantr S; Tantrawatpan C; Tantikanlayaporn D; Kheolamai P
Biosci Rep; 2024 May; 44(5):. PubMed ID: 38687607
[TBL] [Abstract] [Full Text] [Related]
2. Clinical role of NDRG2-based methylation status on survival pattern of glioblastoma.
Swellam M; Khalifa MK; Nageeb AM; Ezz El-Arab L; El-Mahdy M; El-Bahy K; Sayed Mahmoud M
Int J Immunopathol Pharmacol; 2024; 38():3946320241250294. PubMed ID: 38686946
[TBL] [Abstract] [Full Text] [Related]
3. Design, Synthesis, and Investigation of the Pharmacokinetics and Anticancer Activities of Indenoisoquinoline Derivatives That Stabilize the G-Quadruplex in the
Han Y; Buric A; Chintareddy V; DeMoss M; Chen L; Dickerhoff J; De Dios R; Chand P; Riggs R; Yang D; Cushman M
J Med Chem; 2024 May; 67(9):7006-7032. PubMed ID: 38668707
[TBL] [Abstract] [Full Text] [Related]
4. PUMC-MB1 is a novel group 3 medulloblastoma preclinical model, sensitive to PI3K/mTOR dual inhibitor.
Wang S; Zhang D; Wang J; Peng X; Sun H; Ji Y; Yang Z; Bian X; Hou Y; Ge M; Liu Y
J Neurooncol; 2024 May; 168(1):139-149. PubMed ID: 38662151
[TBL] [Abstract] [Full Text] [Related]
5. Hypoxia-induced TREM1 promotes mesenchymal-like states of glioma stem cells via alternatively activating tumor-associated macrophages.
Dong M; Zhang X; Peng P; Chen Z; Zhang Y; Wan L; Xiang W; Liu G; Guo Y; Xiao Q; Wang B; Guo D; Zhu M; Yu X; Wan F
Cancer Lett; 2024 May; 590():216801. PubMed ID: 38479552
[TBL] [Abstract] [Full Text] [Related]
6. A therapeutically targetable positive feedback loop between lnc-HLX-2-7, HLX, and myc that promotes group 3 medulloblastoma.
Katsushima K; Joshi K; Yuan M; Romero B; Batish M; Stapleton S; Jallo G; Kolanthai E; Seal S; Saulnier O; Taylor MD; Wechsler-Reya RJ; Eberhart CG; Perera RJ
Cell Rep; 2024 Mar; 43(3):113938. PubMed ID: 38460130
[TBL] [Abstract] [Full Text] [Related]
7. PRIM2: A Marker of myc-driven Hyper-proliferation, Disease Progression, Tumor Aggressiveness and Poor Survival in Glioma Patients.
Sun R; Shao X; Akter F; Zahid KR; Yao S; Ma L; Xu G
Cancer Genomics Proteomics; 2024; 21(2):186-202. PubMed ID: 38423596
[TBL] [Abstract] [Full Text] [Related]
8. AF1q is a universal marker of neuroblastoma that sustains N-myc expression and drives tumorigenesis.
Oskouian B; Lee JY; Asgharzadeh S; Khan R; Zhang M; Weisbrod JR; Choi YJ; Puri L; Aguilar AE; Zhao P; Saba JD
Oncogene; 2024 Apr; 43(16):1203-1213. PubMed ID: 38413795
[TBL] [Abstract] [Full Text] [Related]
9. Development of a high-throughput screening platform to identify new therapeutic agents for Medulloblastoma Group 3.
Fallon I; Hernando H; Almacellas-Rabaiget O; Marti-Fuster B; Spadoni C; Bigner DD; Méndez E
SLAS Discov; 2024 Mar; 29(2):100147. PubMed ID: 38355016
[TBL] [Abstract] [Full Text] [Related]
10. Therapeutic interventions on human breast cancer xenografts promote systemic dissemination of oncogenes.
Raghuram GV; Pal K; Sriram G; Khan A; Joshi R; Jadhav V; Shinde S; Shaikh A; Rane B; Kangne H; Mittra I
PLoS One; 2024; 19(2):e0298042. PubMed ID: 38346047
[TBL] [Abstract] [Full Text] [Related]
11. TRIM25 promotes glioblastoma cell growth and invasion via regulation of the PRMT1/c-myc pathway by targeting the splicing factor NONO.
Chen Y; Xu X; Ding K; Tang T; Cai F; Zhang H; Chen Z; Qi Y; Fu Z; Zhu G; Dou Z; Xu J; Chen G; Wu Q; Ji J; Zhang J
J Exp Clin Cancer Res; 2024 Feb; 43(1):39. PubMed ID: 38303029
[TBL] [Abstract] [Full Text] [Related]
12. The dopamine receptor D1 inhibitor, SKF83566, suppresses GBM stemness and invasion through the DRD1-c-myc-UHRF1 interactions.
Xue Z; Zhang Y; Zhao R; Liu X; Grützmann K; Klink B; Zhang X; Wang S; Zhao W; Sun Y; Han M; Wang X; Hu Y; Liu X; Yang N; Qiu C; Li W; Huang B; Li X; Bjerkvig R; Wang J; Zhou W
J Exp Clin Cancer Res; 2024 Jan; 43(1):25. PubMed ID: 38246990
[TBL] [Abstract] [Full Text] [Related]
13. DNMT3a-mediated upregulation of the stress inducible protein sestrin-2 contributes to malignant transformation of human bronchial epithelial cells following nickel exposure.
Wang X; Tian Z; He L; Meng H; Zhu J; Li Y; Wang J; Hua X; Huang H; Huang C
Ecotoxicol Environ Saf; 2024 Feb; 271():115954. PubMed ID: 38232523
[TBL] [Abstract] [Full Text] [Related]
14. Ribogenesis boosts controlled by HEATR1-myc interplay promote transition into brain tumour growth.
Diaz LR; Gil-Ranedo J; Jaworek KJ; Nsek N; Marques JP; Costa E; Hilton DA; Bieluczyk H; Warrington O; Hanemann CO; Futschik ME; Bossing T; Barros CS
EMBO Rep; 2024 Jan; 25(1):168-197. PubMed ID: 38225354
[TBL] [Abstract] [Full Text] [Related]
15. Sulforaphane suppresses cell proliferation and induces apoptosis in glioma via the ACTL6A/PGK1 axis.
Peng ZT; Hu R; Fu JY
Toxicol Mech Methods; 2024 Jun; 34(5):507-516. PubMed ID: 38221767
[TBL] [Abstract] [Full Text] [Related]
16. Marinopyrrole derivative MP1 as a novel anti-cancer agent in group 3 myc-amplified Medulloblastoma.
Coulter DW; Chhonker YS; Kumar D; Kesherwani V; Aldhafiri WN; McIntyre EM; Alexander G; Ray S; Joshi SS; Li R; Murry DJ; Chaturvedi NK
J Exp Clin Cancer Res; 2024 Jan; 43(1):18. PubMed ID: 38200580
[TBL] [Abstract] [Full Text] [Related]
17. Combination drug screen identifies synergistic drug interaction of BCL-XL and class I histone deacetylase inhibitors in myc-amplified medulloblastoma cells.
Zeuner S; Vollmer J; Sigaud R; Oppermann S; Peterziel H; ElHarouni D; Oehme I; Witt O; Milde T; Ecker J
J Neurooncol; 2024 Jan; 166(1):99-112. PubMed ID: 38184819
[TBL] [Abstract] [Full Text] [Related]
18. Antitumor efficacy of a sequence-specific DNA-targeted γPNA-based c-myc inhibitor.
Malik S; Pradeep SP; Kumar V; Xiao Y; Deng Y; Fan R; Vasquez JC; Singh V; Bahal R
Cell Rep Med; 2024 Jan; 5(1):101354. PubMed ID: 38183981
[TBL] [Abstract] [Full Text] [Related]
19. Translation of non-canonical open reading frames as a cancer cell survival mechanism in childhood medulloblastoma.
Hofman DA; Ruiz-Orera J; Yannuzzi I; Murugesan R; Brown A; Clauser KR; Condurat AL; van Dinter JT; Engels SAG; Goodale A; van der Lugt J; Abid T; Wang L; Zhou KN; Vogelzang J; Ligon KL; Phoenix TN; Roth JA; Root DE; Hubner N; Golub TR; Bandopadhayay P; van Heesch S; Prensner JR
Mol Cell; 2024 Jan; 84(2):261-276.e18. PubMed ID: 38176414
[TBL] [Abstract] [Full Text] [Related]
20. EXOSC5 maintains cancer stem cell activity in endometrial cancer by regulating the NTN4/integrin β1 signalling axis.
Huang YH; Wang WL; Wang PH; Lee HT; Chang WW
Int J Biol Sci; 2024; 20(1):265-279. PubMed ID: 38164180
[TBL] [Abstract] [Full Text] [Related]
[Next]
